Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Elizabeth Holmes heads to court today to face multiple criminal fraud charges that could land the Theranos founder and CEO in prison for more than a decade.
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
Last spring he joined Fountain Therapeutics as CEO, a company that merges artificial intelligence (AI) with machine learning (ML) to develop therapeutics for degenerative diseases.
The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.
Exelixis is mourning the loss of two veteran executives—Dr. Gisela M. Schwab, president, Product Development and Medical Affairs and CMO, and Jon Berndt, senior VP of Sales.
Adaptimmune will be responsible for developing clinical T-cell candidates for the two companies through its induced pluripotent stem cell (iPSC) derived allogeneic platform.
Scopus Biopharma recently launched Duet Therapeutics to integrate its immunotherapy assets’ management and clinical development with Olimmune.
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
The life sciences industry was well-represented, with a handful of names featured in the top 100.